AbSci, a Vancouver, Wash.-based protein printing company, closed a $10.4M Series D financing.

The round was led by KBI Biopharma and JSR Life Sciences with participation from existing investors Phoenix Venture Partners, Oregon Venture Fund, WRF Capital, and Columbia Ventures Corporation.

Its patented SoluPro™ expression platform rapidly produces complex proteins, ranging from mAbs, Fabs, enzymes, hormones and peptides, to emerging novel classes of biotherapeutics.

In addition, AbSci and KBI Biopharma have entered into an exclusive co-marketing agreement to jointly market and promote each other’s technologies, products, and services.

Under the agreement, KBI Biopharma, a biopharmaceutical CDMO providing fully integrated biopharmaceutical development and manufacturing services, has the exclusive right to market AbSci’s Protein Printing™ technology worldwide and is AbSci’s preferred CDMO for industrial scale-up of biologics developed using AbSci technology. | To read full story, visit https://startuparound.com/read/1578994207.1758592/AbSci-Raises-$15.4M-in-Series-D-Funding?ref=audio_experience